References
- Herling M, Rassidakis GZ, Jones D, Schmitt-Graeff A, Sarris AH, Medeiros LJ. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol 2004;35:455–459.
- AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998;103:100–109.
- Suh YK, Shin SS, Koo CH. Synchronous Hodgkin disease and granulocytic sarcoma with no prior therapy. Hum Pathol 1996;27:1103–1106.
- van Leeuwen FE, Klokman WJ, Hagenbeek A, et al Second cancer risk following Hodgkin disease: a 20-year follow-up study. J Clin Oncol 1994;12:312–325.
- Schonfeld SJ, Gilbert ES, Dores GM, et al Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 2006;98:215–218.
- Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233–255.
- Surveillance epidemiology and end results database [internet]. Available online at: http:\\www.seer.cancer.gov, accessed 15 July 2009.
- Hiddemann W, Schmitz N, Pfreundschuh M, et al Treatment of refractory Hodgkin disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group. Cancer 1990;66:838–843.